
Cardiol Therapeutics Inc
TSX:CRDL

Cardiol Therapeutics Inc
Net Issuance of Common Stock
Cardiol Therapeutics Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Cardiol Therapeutics Inc
TSX:CRDL
|
Net Issuance of Common Stock
CA$21.4m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
|
![]() |
Bausch Health Companies Inc
TSX:BHC
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Canopy Growth Corp
TSX:WEED
|
Net Issuance of Common Stock
CA$394m
|
CAGR 3-Years
263%
|
CAGR 5-Years
56%
|
CAGR 10-Years
45%
|
|
![]() |
Sundial Growers Inc
NASDAQ:SNDL
|
Net Issuance of Common Stock
-CA$28.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Cronos Group Inc
TSX:CRON
|
Net Issuance of Common Stock
-$3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Net Issuance of Common Stock
-CA$10.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
Cardiol Therapeutics Inc
Glance View
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

See Also
What is Cardiol Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
21.4m
CAD
Based on the financial report for Mar 31, 2025, Cardiol Therapeutics Inc's Net Issuance of Common Stock amounts to 21.4m CAD.
What is Cardiol Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
120%
Over the last year, the Net Issuance of Common Stock growth was 23 673%. The average annual Net Issuance of Common Stock growth rates for Cardiol Therapeutics Inc have been -37% over the past three years , 120% over the past five years .